Literature DB >> 18509351

Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma.

J Dien Bard1, P Gelebart, M Anand, H M Amin, R Lai.   

Abstract

One of the characteristic features of anaplastic lymphoma kinase (ALK)(+), anaplastic large cell lymphoma (ALK(+)ALCL) is the constitutive activation of signal transducers and activators of transcription-3 (STAT3), a defect believed to be important for the pathogenesis of these tumors. In this report, we describe the existence of an autocrine stimulatory loop involving interleukin-22 (IL-22) that contributes to STAT3 activation and tumorigenicity of ALK(+)ALCL. The IL-22 receptor, a heterodimer composed of IL-22R1 and IL-10R2, was expressed in all ALK(+)ALCL cell lines and tumors examined. The expression of IL-22R1 in ALK(+)ALCL is aberrant, as this protein is absent in benign lymphocytes. Although ALK(+)ALCL cells produce endogenous IL-22, addition of recombinant IL-22 to ALK(+)ALCL cell lines significantly increased STAT3 activation, cell proliferation and colony formation in soft agar. Opposite biological effects were observed in cells treated with recombinant IL-22 binding protein (a naturally occurring IL-22 decoy) or IL-22-neutralizing antibody. Nucleophosmin (NPM)-ALK, the characteristic fusion gene oncoprotein expressed in ALK(+)ALCL, directly contributes to the aberrant expression of IL-22R1, as transfection of NPM-ALK in Jurkat cells-induced IL-22R1 expression and IL-22-mediated STAT3 activation. To conclude, for the first time, we demonstrate the importance of the IL-22 autocrine pathway in a lymphoid malignancy, and reveal yet another novel function of NPM-ALK.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18509351      PMCID: PMC3429118          DOI: 10.1038/leu.2008.129

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  40 in total

Review 1.  The p38 signal transduction pathway: activation and function.

Authors:  K Ono; J Han
Journal:  Cell Signal       Date:  2000-01       Impact factor: 4.315

2.  Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta ) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes.

Authors:  S V Kotenko; L S Izotova; O V Mirochnitchenko; E Esterova; H Dickensheets; R P Donnelly; S Pestka
Journal:  J Biol Chem       Date:  2000-10-16       Impact factor: 5.157

3.  Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9.

Authors:  L Dumoutier; J Louahed; J C Renauld
Journal:  J Immunol       Date:  2000-02-15       Impact factor: 5.422

Review 4.  Pathobiology of ALK+ anaplastic large-cell lymphoma.

Authors:  Hesham M Amin; Raymond Lai
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

5.  Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R.

Authors:  M H Xie; S Aggarwal; W H Ho; J Foster; Z Zhang; J Stinson; W I Wood; A D Goddard; A L Gurney
Journal:  J Biol Chem       Date:  2000-10-06       Impact factor: 5.157

6.  Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22.

Authors:  L Dumoutier; D Lejeune; D Colau; J C Renauld
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

7.  Is there an interaction between interleukin-10 and interleukin-22?

Authors:  K Wolk; E Witte; U Reineke; K Witte; M Friedrich; W Sterry; K Asadullah; H-D Volk; R Sabat
Journal:  Genes Immun       Date:  2005-02       Impact factor: 2.676

8.  Requirement of activation of JNK and p38 for environmental stress-induced erythroid differentiation and apoptosis and of inhibition of ERK for apoptosis.

Authors:  Y Nagata; K Todokoro
Journal:  Blood       Date:  1999-08-01       Impact factor: 22.113

9.  Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis.

Authors:  A Slupianek; M Nieborowska-Skorska; G Hoser; A Morrione; M Majewski; L Xue; S W Morris; M A Wasik; T Skorski
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

10.  A novel, soluble homologue of the human IL-10 receptor with preferential expression in placenta.

Authors:  B H Gruenberg; A Schoenemeyer; B Weiss; L Toschi; S Kunz; K Wolk; K Asadullah; R Sabat
Journal:  Genes Immun       Date:  2001-10       Impact factor: 2.676

View more
  42 in total

1.  Interleukin 22 signaling promotes cell growth in mantle cell lymphoma.

Authors:  Pascal Gelebart; Zoulika Zak; Jennifer Dien-Bard; Mona Anand; Raymond Lai
Journal:  Transl Oncol       Date:  2011-02-01       Impact factor: 4.243

2.  A novel role for IL-22R1 as a driver of inflammation.

Authors:  Ram Savan; Adelle P McFarland; Della A Reynolds; Lionel Feigenbaum; Karthika Ramakrishnan; Megan Karwan; Hidekazu Shirota; Dennis M Klinman; Kieron Dunleavy; Stefania Pittaluga; Stephen K Anderson; Raymond P Donnelly; Wyndham H Wilson; Howard A Young
Journal:  Blood       Date:  2010-10-22       Impact factor: 22.113

3.  β-catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

Authors:  Mona Anand; Raymond Lai; Pascal Gelebart
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

4.  Pro-tumour activity of interleukin-22 in HPAFII human pancreatic cancer cells.

Authors:  L M Curd; S E Favors; R K Gregg
Journal:  Clin Exp Immunol       Date:  2012-05       Impact factor: 4.330

5.  IL-22 promotes the migration and invasion of gastric cancer cells via IL-22R1/AKT/MMP-9 signaling.

Authors:  Yinghua Ji; Xiaoyu Yang; Jinsong Li; Zhihong Lu; Xiaorui Li; Jian Yu; Na Li
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

6.  IL-18 Drives ILC3 Proliferation and Promotes IL-22 Production via NF-κB.

Authors:  Aaron R Victor; Ansel P Nalin; Wenjuan Dong; Susan McClory; Min Wei; Charlene Mao; Raleigh D Kladney; Youssef Youssef; Wing Keung Chan; Edward L Briercheck; Tiffany Hughes; Steven D Scoville; Jason R Pitarresi; Charlie Chen; Sarah Manz; Lai-Chu Wu; Jianying Zhang; Michael C Ostrowski; Aharon G Freud; Gustavo W Leone; Michael A Caligiuri; Jianhua Yu
Journal:  J Immunol       Date:  2017-08-25       Impact factor: 5.422

7.  The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update.

Authors:  Raymond Lai; Robert J Ingham
Journal:  Ther Adv Hematol       Date:  2013-04

8.  New developments in the pathology of malignant lymphoma: a review of the literature published from May to July 2008.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2008-09       Impact factor: 0.196

9.  Functional characterization of the kinase activation loop in nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) using tandem affinity purification and liquid chromatography-mass spectrometry.

Authors:  Peng Wang; Fang Wu; Yupo Ma; Liang Li; Raymond Lai; Leah C Young
Journal:  J Biol Chem       Date:  2009-11-02       Impact factor: 5.157

Review 10.  The important role of T cells and receptor expression in Sjögren's syndrome.

Authors:  A Karabiyik; A B Peck; C Q Nguyen
Journal:  Scand J Immunol       Date:  2013-08       Impact factor: 3.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.